Cannabis Science (CBIS) Congratulates U.S. Congress for Historical Move to Stop the Department of Justice (DOJ) Impeding Legal State Medical Cannabis Operations; Perfect Timing for CBIS Large Investment in California
COLORADO SPRINGS, Colo., Dec. 15, 2014 /PRNewswire/ — Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development and related consulting, congratulates the U.S. Congress for making serious Medical Cannabis History by pulling this fiscal year’s funding for any DOJ actions that would stop legal state medical cannabis programs and operations. The final bill passed the House last week and the Senate over the weekend.
The President announced his intention to sign the bill into law in the coming days. Cannabis Science’s recently announced expansion within the California medical cannabis market is even more compelling, and patients in California and other legal medical cannabis states can rest easy that they will not be denied needed medicines.
“When President Obama signs this landmark bipartisan spending bill, the federal government will have taken the most significant stand to date to protect state medical cannabis programs from federal interference. This is great news for Cannabis Science, particularly in light of the Company’s substantial new investment in California operations, and it is incredibly impactful for patients,” said Chad S. Johnson, Esq., Director, COO, & General Counsel of Cannabis Science, Inc.
Americans for Safe Access: “Patients Applaud Congressional Restriction on Federal Medical Marijuana Enforcement in Omnibus Budget Bill; Historic measure is similar to House amendment passed earlier this year aimed at ending DOJ/DEA interference”
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Cannabis Science, Inc.
Raymond C. Dabney, Director, President & CEO, Co-Founder
To view the original version on PR Newswire, visit:https://www.prnewswire.com/news-releases/cannabis-science-cbis-congratulates-us-congress-for-historical-move-to-stop-the-department-of-justice-doj-impeding-legal-state-medical-cannabis-operations-perfect-timing-for-cbis-large-investment-in-california-300009510.html
MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | firstname.lastname@example.org